Insights into the roles of miRNAs; miR-193 as one of small molecular silencer in osteosarcoma therapy

• Main Authors: Sama Izadpanah, Parastoo Shabani, Ali Aghebati-Maleki, Elham Baghbani, Amir Baghbanzadeh, Ali Fotouhi, Babak Bakhshinejad, Leili Aghebati-Maleki, Behzad Baradaran
• Format: Article
• Language: English
• Published: Elsevier 2019-03-01
• Series: Biomedicine & Pharmacotherapy
• Subjects: Cancer; microRNA; miR-193; Osteosarcoma
• Online Access: http://www.sciencedirect.com/science/article/pii/S0753332218354143
• ISSN: 0753-3322

Today, cancer is one of the most common causes of death. Osteosarcoma (OS) is a tumor in long bones and its prevalence is high in teenagers and young people. Among the methods that used to treat cancer, one can name chemotherapy, surgery, and radiotherapy. Since these methods have some disadvantages and they are not absolutely successful, the use of microRNAs (miRNAs) is very useful in diagnosis and treatment of OS. MiRNAs are small non-coding RNA molecules, containing 18–25 nucleotides, which are involved in the regulation of gene expression via binding to messenger RNA (mRNA). These RNAs are divided into two classes of suppressors and oncogenes. During OS, there is aberrant expression of several miRNAs. Among these miRNAs are downregulation of miR-193 that has been associated with cancer occurrence. The aim of the current manuscript is to have overview on the treatment approaches of OS with special focus on miR-193.